Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Nov 11 - release its third quarter 2021 financial results
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Snowballgrowthon Nov 11, 2021 2:19pm
118 Views
Post# 34116151

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nov 11 - release its third quarter 2021 financial results

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Nov 11 - release its third quarter 2021 financial results
MrMugsy wrote:
wagyusteak wrote:
Snowballgrowth wrote:
Chianchin wrote: You mean.... GUD steady as she goes down from $10.50 to $5 and to $2.99??? Yep you got it correct for once


After a deep analysis, I guess you will be very disapointed by the numbers today. And you will continue your talking about past stock price. I could be wrong but it is my prediction. 
 


great numbers imo. Free cash flow is almost $50m YTD. Too cheap. Haha
 


Yes - Revenue and margins were good - buys us time on pricing and even on improved currencies in the future.

Great cashflow from operations - should be paying for our growth nicely one day.

We had an investment loss (were warned) - will see that fluctuate but also become less of an effect on the numbers as revenues grow (investment gains/losses).

Setting up nicely for Q4 and yearend numbers.

As EXELON rolls in - other drugs will also be coming to market ... along with new drugs added to the pipeline.  

Cheers!


Huge growth and great contribution from many products

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities